Strategic Partnerships Serametrix collaborates with premier cancer research institutions such as LICR, MSK, and Cancer Research Limited to develop and standardize immune monitoring technologies, highlighting opportunities to position complementary assays and integrated solutions to similar leading centers or academic networks.

Acquisition History Historical acquisition by Caprion Biosciences indicates a strategic consolidation in immune monitoring services, suggesting potential opportunities to engage Caprion’s broader customer base and leverage cross-sell of Serametrix's standardized immunoassays to existing Caprion clients.

ImmunoMonitoring Focus Specialization in immune monitoring for cancer immunotherapies and MDSC analysis positions Serametrix to offer targeted assays, data services, and translational support to biotech and pharma companies advancing I-O therapies seeking robust pharmacodynamic readouts.

Clinical Trial Footprint Small to mid-sized team (11-50 employees) with a clear market in clinical trial labs presents a scalable entry point for project-based collaborations, pilot studies, and white-labeling of standardized immune assays for sponsor-driven trials.

Digital & Global Reach Active web presence and tech stack (WordPress, Joomla, cloud hosting) coupled with partnerships suggests opportunities to expand digital marketing, lead generation, and global service delivery, including outreach to large CROs and biotech suppliers seeking validated immune monitoring capabilities.